Latent Tuberculosis Infection and Associated Risk Factors among People Living with HIV and HIV-Uninfected Individuals in Lithuania.
HIV
LTBI
TB
prevalence
risk factors
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
28 Jul 2023
28 Jul 2023
Historique:
received:
21
06
2023
revised:
20
07
2023
accepted:
26
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
People living with HIV (PLHIV) with latent tuberculosis infection (LTBI) are at increased risk of tuberculosis (TB) reactivation compared to the HIV-negative population. Lithuania belongs to the 18 high-priority TB countries in the European region. The aim of this study was to compare the prevalence of LTBI and LTBI-related risk factors between PLHIV and HIV-uninfected populations. A cross-sectional study was conducted in three Lithuanian Infectious Diseases centres from August 2018 to May 2022 using the interferon gamma release assay (IGRA) and tuberculin skin test (TST) in Vilnius, and IGRA only in Siauliai and Klaipeda. Cohen's kappa was used to assess IGRA and TST agreement. A structured questionnaire was completed by the study participants. LTBI-related risk factors were identified using a multivariable logistic regression model. In total, 391 PLHIV and 443 HIV-uninfected individuals enrolled, with a median age of 41 (IQR 36-48) and 43 (IQR 36-50), consisting of 69.8% and 65.5% male, respectively. The prevalence of LTBI defined by positive IGRA and/or TST among PLHIV was higher compared to that in the HIV-uninfected population (20.5% vs. 15.3%; OR 1.42; 95% CI 1.02-2.03; The prevalence of LTBI among PLHIV in Lithuania is higher compared to that in the HIV-uninfected population and the European average. The association with IDU in PLHIV emphasizes the need for integrated HIV, TB and substance abuse treatment to provide patient-centred care.
Sections du résumé
BACKGROUND
BACKGROUND
People living with HIV (PLHIV) with latent tuberculosis infection (LTBI) are at increased risk of tuberculosis (TB) reactivation compared to the HIV-negative population. Lithuania belongs to the 18 high-priority TB countries in the European region. The aim of this study was to compare the prevalence of LTBI and LTBI-related risk factors between PLHIV and HIV-uninfected populations.
METHODS
METHODS
A cross-sectional study was conducted in three Lithuanian Infectious Diseases centres from August 2018 to May 2022 using the interferon gamma release assay (IGRA) and tuberculin skin test (TST) in Vilnius, and IGRA only in Siauliai and Klaipeda. Cohen's kappa was used to assess IGRA and TST agreement. A structured questionnaire was completed by the study participants. LTBI-related risk factors were identified using a multivariable logistic regression model.
RESULTS
RESULTS
In total, 391 PLHIV and 443 HIV-uninfected individuals enrolled, with a median age of 41 (IQR 36-48) and 43 (IQR 36-50), consisting of 69.8% and 65.5% male, respectively. The prevalence of LTBI defined by positive IGRA and/or TST among PLHIV was higher compared to that in the HIV-uninfected population (20.5% vs. 15.3%; OR 1.42; 95% CI 1.02-2.03;
CONCLUSIONS
CONCLUSIONS
The prevalence of LTBI among PLHIV in Lithuania is higher compared to that in the HIV-uninfected population and the European average. The association with IDU in PLHIV emphasizes the need for integrated HIV, TB and substance abuse treatment to provide patient-centred care.
Identifiants
pubmed: 37623950
pii: pathogens12080990
doi: 10.3390/pathogens12080990
pmc: PMC10459141
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The Western-Eastern European Partnership Initiative on HIV, Viral Hepatitis and TB (WEEPI, www.weepi.org)
ID : The project "Run-up to programmatic management of latent tuberculosis infection in HIV infected people in Lithuania", Project ID 482020
Références
Lancet Infect Dis. 2022 Jan;22(1):85-96
pubmed: 34499863
BMC Infect Dis. 2021 Oct 6;21(1):1038
pubmed: 34615474
Int J Drug Policy. 2014 Jan;25(1):175-8
pubmed: 24210296
J Int AIDS Soc. 2015 Feb 16;18:19317
pubmed: 25690530
PLoS One. 2013 Aug 27;8(8):e73069
pubmed: 24015285
PLoS One. 2017 Jan 6;12(1):e0169539
pubmed: 28060926
BMC Res Notes. 2019 Aug 16;12(1):515
pubmed: 31420007
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Front Cell Infect Microbiol. 2022 Sep 23;12:1000663
pubmed: 36211970
Eur Respir J. 2018 Jan 18;51(1):
pubmed: 29348181
J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):47-55
pubmed: 23482341
N Engl J Med. 2015 May 28;372(22):2127-35
pubmed: 26017823
JAMA. 2005 Jun 8;293(22):2746-55
pubmed: 15941804
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1168-76
pubmed: 25303140
BMC Infect Dis. 2013 Nov 01;13:513
pubmed: 24176032
Eur Respir J. 2018 Oct 25;52(4):
pubmed: 30361266
J Clin Microbiol. 2004 Feb;42(2):829-31
pubmed: 14766863
PLoS One. 2015 Oct 27;10(10):e0141511
pubmed: 26505997
JAMA. 2000 Apr 19;283(15):2003-7
pubmed: 10789669
Breathe (Sheff). 2021 Sep;17(3):210079
pubmed: 35035549
J Microbiol Immunol Infect. 2016 Oct;49(5):729-736
pubmed: 25442858
Biometrics. 1977 Jun;33(2):363-74
pubmed: 884196
PLoS One. 2023 Mar 23;18(3):e0282046
pubmed: 36952578
Expert Rev Anti Infect Ther. 2016;14(5):489-500
pubmed: 26999724
Lancet Infect Dis. 2017 Nov;17(11):1190-1199
pubmed: 28827142
HIV Med. 2022 Jan;23(1):48-59
pubmed: 34468073
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):230-8
pubmed: 21239993
J Infect. 2020 May;80(5):536-546
pubmed: 32097688
JAMA. 1999 Aug 18;282(7):677-86
pubmed: 10517722
Chest. 2017 Aug;152(2):282-294
pubmed: 28087302
Ann Thorac Med. 2010 Jan;5(1):43-6
pubmed: 20351960
Sci Rep. 2019 Jul 12;9(1):10093
pubmed: 31300686
Vaccine. 2018 Jun 7;36(24):3408-3410
pubmed: 29609965
PLoS One. 2016 Sep 13;11(9):e0161983
pubmed: 27622293
Med Lav. 2020 Jun 26;111(3):170-183
pubmed: 32624559
BMC Infect Dis. 2010 Dec 10;10:348
pubmed: 21143955
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810